RxDoctor Payments Data

Mindy Bixby, DO

Neurology · Laguna Beach, CANPI 1508012139

Payments from drug & device makers

$299,667in general payments, 2019–2025

Across 1,000 payments — averaging $299.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$125K
  • Amneal Pharmaceuticals LLC$101K
  • Abbott$52K
  • Zambon USA Ltd.$8K
  • AbbVie$6K
  • Boston Scientific$4K
  • plus $5K from 32 others
$161,157in research payments, 2019–2025

Across 7 payments — averaging $23,022 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amneal Pharmaceuticals LLC$155K
  • Acadia Pharmaceuticals Inc$6K

What the payments were for

  • Consulting fees$37,27713%
  • Speaking & faculty fees$201,63668%
  • Travel & lodging$37,83713%
  • Food & beverage$16,5136%
  • Education$1,4630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$299,667 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$227,790
Medicare patients
232
Services billed
2,902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa274$311,088
NuplazidPimavanserin Tartrate47$222,075
GocovriAmantadine Hcl44$163,396
IngrezzaValbenazine Tosylate11$89,696
Droxidopa19$74,662
Carbidopa-LevodopaCarbidopa/Levodopa480$27,006
NeuproRotigotine11$23,462
Nurtec OdtRimegepant Sulfate16$17,992
OngentysOpicapone17$17,599
CrexontCarbidopa/Levodopa32$16,630
Rivastigmine71$14,485
Rasagiline Mesylate59$11,183
ExelonRivastigmine11$7,706
Entacapone27$7,562
Carbidopa-Levodopa ErCarbidopa/Levodopa55$5,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Crexont$100,674$327,718306 claims
Acadia Pharmaceuticals IncNuplazid$269$222,07547 claims
MDD US Operations, LLCGocovri$124,522$163,39644 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$60$107,29528 claims
UCB, Inc.Neupro$41$23,46211 claims
PfizerNurtec Odt$27$17,99216 claims
NovartisExelon$226$7,70611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Laguna Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →